UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus
Funding provided by the National Institute of Allergy and Infectious Diseases
Seattle, WA August 18, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced in July that it received funding to expand testing of its broad spectrum innate immune antivirals against Zika virus. This project is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Department of Health and Human Services. This supplemental contract award will be used to evaluate lead broad spectrum antivirals in preclinical models of Zika virus infection.
Zika virus has been named as a global public health emergency by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). “There is a critical need for therapeutics to combat emerging viruses like Zika that are creating a public health crisis across the globe”, said Dr. Shawn Iadonato, Kineta CEO. “We are eager to expand testing of our broad spectrum antivirals in Zika virus, as they have shown compelling preclinical efficacy in other flaviviruses such as Dengue and West Nile virus and have the potential for long term development as a pan-flavivirus therapy.”
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201500011C.
Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.